HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?  Giuseppe Bruno, Annalisa.

Slides:



Advertisements
Similar presentations
Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 TURQUOISE-II Phase 3 Treatment.
Advertisements

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
Compensated Cirrhosis
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Development of a foundation for a case definition of post-treatment Lyme disease syndrome John N. Aucott, Lauren A. Crowder, Kathleen B. Kortte International.
Robert Koch and the ‘golden age’ of bacteriology Steve M. Blevins, Michael S. Bronze International Journal of Infectious Diseases Volume 14, Issue 9, Pages.
Syndromic classification of rickettsioses: an approach for clinical practice Álvaro A. Faccini-Martínez, Lara García-Álvarez, Marylin Hidalgo, José A.
Infective endocarditis caused by Streptococcus bovis complicated by a superior mesenteric artery mycotic aneurysm and systemic septic emboli in a patient.
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis 
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
Soraya E. Morales-López, Jayr A
International Journal of Infectious Diseases
International Journal of Infectious Diseases
International Journal of Infectious Diseases
Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review  X.-F. Gao, Z.-W. Yang, J. Li  International.
Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared  Gilles Wandeler, Lloyd Mulenga, Michael.
Laboratory diagnosis and biosafety issues of biological warfare agents
Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.
Luis A. Marcos, Zengmin Yan 
Phase 2 Treatment Naïve HIV Coinfection
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Borrelia burgdorferi infection and Lyme disease in children
Volume 69, Issue 2, Pages (August 2018)
Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.
Approach to diagnosis of infective endocarditis
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis 
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Volume 153, Issue 4, Pages (October 2017)
Virological tools to diagnose and monitor hepatitis C virus infection
Peginterferon alfa-2b plus ribavirin for chronic hepatitis
Volume 59, Issue 4, Pages (October 2013)
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes:
Jordan J. Feld, Graham R. Foster  Journal of Hepatology 
Yasuhiko Sugawara, Masatoshi Makuuchi 
Volume 155, Issue 5, Pages e2 (November 2018)
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection
Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis  Ashwani K. Singal, Amanpal Singh, Sathya.
Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon.
Training for the infectious diseases speciality in Norway
New HCV therapies on the horizon
Retrospective study of CMV retinitis in patients with AIDS
Laboratory diagnosis and biosafety issues of biological warfare agents
C. Fabrizio, A. Procopio  Clinical Microbiology and Infection 
Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice  J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman  Clinical.
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Volume 142, Issue 6, Pages (May 2012)
What Does the Future Hold and What Will It Mean for Patients?
Laboratory diagnosis of Clostridium difficile disease
Rafael Esteban, Maria Buti  Gastroenterology 
Factors related to the chronicity and evolution of hepatitis C infection in patients co- infected by the human immunodeficiency virus  R. Pérez-Cano, C.
Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection  E. Knops, E. Heger  Clinical Microbiology.
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Hepatitis C treatment in patients with kidney disease
Abstracts Clinical Microbiology and Infection
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
Phase 3 Treatment-Naïve and Treatment-Experienced
New patterns of HIV-1 resistance during HAART
J.A. Pérez-Molina, F. Fernández  Clinical Microbiology and Infection 
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.
Reversion of disease manifestations after HCV eradication
Presentation transcript:

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?  Giuseppe Bruno, Annalisa Saracino, Luigia Scudeller, Claudia Fabrizio, Raffaele Dell’Acqua, Eugenio Milano, Michele Milella, Nicoletta Ladisa, Laura Monno, Gioacchino Angarano  International Journal of Infectious Diseases  Volume 62, Pages 64-71 (September 2017) DOI: 10.1016/j.ijid.2017.07.001 Copyright © 2017 The Author(s) Terms and Conditions

Figure 1 SVR12 rates according to the use of RBV, diagnosis of cirrhosis, platelet count, albumin level, previous anti-HCV therapy, HIV infection, and HCV genotype 3 vs. other genotypes. Abbreviations: SVR12, sustained virological response (undetectability lasting for 12 consecutive weeks after the cessation of treatment); RBV, ribavirin; GT, genotype. International Journal of Infectious Diseases 2017 62, 64-71DOI: (10.1016/j.ijid.2017.07.001) Copyright © 2017 The Author(s) Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.